The European Commission, following the recommendation of the European Medicines Agency, has authorized the use of Gardasil the quadrivalent vaccine against the human papilloma virus (HPV), in children from 9 years of age, and young people from 16 to 26 years, which makes it the first vaccine against this virus that can be administered to both sexes.

The drug, marketed by Sanofi Pasteur MSD, and available since 2006, protects against four types of the virus (6, 11, 16 and 18), and its data sheet has been updated based on the results of a clinical trial in which its effectiveness has been confirmed to preventgenital warts, a common condition in youth and whose incidence is increasing.

In addition, this latest study adds to others that show the high immune response produced by the vaccine in adolescents between 9 and 15 years.

The vaccination of men against HPV can help reduce the circulation of the virus, and thus improve the results of the vaccine in young women.

As explained by Benoit Soubeyrand, medical director of Sanofi Pasteur MSD in Europe, as well as preventing the appearance of genital warts in young boys and girls, Gardasil It can contribute to reduce the circulation of HPV and, in this way, also improve the results of vaccination in young women.

The clinical efficacy of the vaccine has also been included in the new vaccine's technical data sheet to prevent precancerous lesions of anus caused by types 16 and 18 of HPV, as has been proven in a sub-study conducted with men who claimed to have sex with other men. Both types are responsible for 70% of precancerous lesions of the anus, 80% of anal cancers, and 70% of penile cancers.

This study, as indicated by company sources, has been based on precancerous lesions as a marker of anal cancer, since it is not possible to study the prevention of this pathology for ethical reasons.


Cancer Moonshot III: Translational Medicine (November 2019).